MADRIGAL PHARMACEUTICALS, INC. (MDGL) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21
	10-Q	10-Q	8-K	10-Q	10-Q	10-K	10-Q	10-Q
Revenues				0.0	0.0	0.0	0.0	0.0
Cost of goods sold				0.0	0.0	0.0	0.0	0.0
Gross profit				0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]				41.4	39.8	37.3	31.7	28.9
General and administrative				41.4	39.8	37.3	31.7	28.9
Research and development				214.2	207.3	205.2	205.7	204.1
EBITDA [+]				-255.2	-246.7	-242.1	-237.0	-232.6
EBITDA growth				9.7%	11.5%	17.4%	34.1%	63.6%
Depreciation and amortization				0.4	0.4	0.4	0.4	0.4
EBIT [+]				-255.6	-247.1	-242.5	-237.4	-233.1
EBIT growth				9.7%	11.5%	17.3%	34.1%	63.6%
Interest income, net [+]				-0.3	0.3	0.4	0.7	1.5
Interest expense				0.8
Interest income				0.5	0.3	0.4	0.7	1.5
Other income (expense), net						0.3
Pre-tax income				-255.9	-246.8	-241.8	-236.4	-231.3
Income taxes				0.0	0.0	0.0	0.0	0.0
Tax rate				0.0%	0.0%	0.0%	0.0%	0.0%
Net income				-255.9	-246.8	-241.8	-236.4	-231.3

Basic EPS [+]				($15.07)	($14.65)	($14.63)	($14.66)	($14.61)
Growth				3.1%	4.1%	11.7%	32.4%	67.7%
Diluted EPS [+]				($15.07)	($14.65)	($14.63)	($14.66)	($14.61)
Growth				3.1%	4.1%	11.7%	32.4%	67.7%

Shares outstanding (basic) [+]				17.0	16.8	16.5	16.1	15.8
Growth				7.3%	8.4%	7.1%	4.5%	2.7%
Shares outstanding (diluted) [+]				17.0	16.8	16.5	16.1	15.8
Growth				7.3%	8.4%	7.1%	4.5%	2.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.